TGFβ, as a tumor suppressor, acts as a double-edged sword and activates anti-inflammatory signaling, but when its receptor loses function during malignant transformation, it indirectly acts as an immunosuppressant, promoting vascularization and metastasis, and thus enhances the malignancy of carcinomas [132] as mentioned earlier [20]. Here, TGFB1 is linked to carcinoma.